Member Profile

In 2007, BIONET successfully completed initial publicoffering (IPO) and became the first publicly tradedcompany in the stem cell and genetic testing industry ofTaiwan. Furthermore, as a pioneer in providing MesenchymalStem Cell banking service in Asia, BIONET hasreceived matching inquiries through the database formore than one thousand times from over 30 differentcountries and has released around 364 stem cell unitsfor cellular therapies throughout the world. Currently,BIONET is the largest enterprise in the cell therapy andgenetic testing industry in Taiwan, To date, BIONETowns 25 patents and continues to commit to researchand applications in the field of Regenerative Medicine.BIONET has transplantation experience from child toadult, and owns a Mesenchymal Stem Cell Bank withsufficient cells to further produce units for domestic andforeign medical use. Several world-leading pharmaceuticalcompanies also recognize the high standards of Bionet’slaboratory and rigorous operation of the staff, and havecommissioned the company to conduct cell sampleprocessing. BIONET will continue to grow withsolid foundation in CDMO, skin care / hair-growthdevelopment and cell processing.
The Genetics Generation Advancement Corporation(GGA Corp.) is a subsidiary of BIONET. GGA focuseson five major disciplines of precision medicine:maternal-fetal precision medicine, pediatric diseasediagnosis, companion diagnostics, non-invasivecancer screening and precision health management.In 2012, GGA became the first publicly traded companyin Taiwan to specialize in genetic testing and scientificinformatics.GGA was selected by “Deloitte AP Technology Fast500” in 2012 and 2013, which recognizes and encouragesthe development of the biotechnology industry in Taiwan.GGA is the first laboratory in Taiwan to be certified bythe College of American Pathologists (CAP), theTaiwan Accreditation Foundation (TAF), and theAffymetrix® Service Provider and Illumina® CSPro.The laboratory has also passed the examination forhepatitis C viral NS5A mutation screening as held bythe Taiwanese Society of Molecular Medicine.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2005 The mesenchymal stem cell bank was established, which has core technology and manufacturing capabilities for the medical-grade cell therapy products. With the “Hybrid Model” combining the advantages of private banking and public donation, BIONET assisted Chinese people at home and abroad to match medical cord blood transplants.
   2007 BIONET successfully completed initial public offering (IPO) and became the first publicly traded company in the stem cell.
   2011 BIONET is the first private cord blood bank in Asia to be accredited by the American Association of Blood Banks (AABB). Moreover, BIONET is the first company in the world to receive accreditations in three categories from AABB, including Cord Blood (CB), Somatic cell and Hematopoietic progenitor cells (HPC), and Mesenchymal Stem Cells (MSC). So far, it has 8 times of certification by AABB.
   2014 BIONET stepped into the aesthetic medicine market by developing advanced skin care technology to promote the application of Stem Cell technology and share the benefits with the public, also launched RE. O series skin care products. BIONET built a GMP facility in Southern Taiwan Science Park to offer OEM services to domestic and foreign markets.
   2017 BIONET was cooperated with medical center to initiate the clinical trial about “MSC to treat severe lung injury, pneumonia, and sepsis with acute respiratory distress syndrome (ARDS) caused by influenza, and other virus”. This study was recently published in the international critical care journal “Critical Care Medicine”.
   2020 The “Autologous adipose-derived stem cell transplantation over 6 weeks chronic ulcer or chronic wounds project” was approved by the Ministry of Health and Welfare. “Special Administrative Measures” was approved to treat “stage 4 solid cancer” through “autoimmune cells”.
   2020 Approved for Compassionate Use, and cooperated with many large medical centers to assist in the treatment of acute respiratory distress syndrome (ARDS) caused by infection with covid-19; BIONET’s Mesenchymal Stem Cell Bank has sufficient cells to produce units for domestic and foreign medical use.
   2021 BIONET has invested in respiratory-related disease research more than 15 years, and was approved by Ministry of Health and Welfare for the treatment of acute respiratory distress syndrome (ARDS) phase II human clinical trials with the medical center.